Whalesbook
Akums Drugs Charts Growth Amidst Regulatory Scrutiny
Akums Drugs and Pharmaceuticals Limited (ADPL) has announced its financial results for the third quarter of fiscal year 2026, showcasing impressive top-line growth while navigating significant regulatory headwinds. The company reported a 14.8% year-over-year (YoY) increase in consolidated revenue, reaching ₹1,160 Crore, driven by strong performance across its key segments. Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA - a measure of operational profitability) also saw a healthy 21% YoY jump to ₹147 Crore, with the EBITDA margin expanding by 65 basis points to 12.7%. Profit After Tax (PAT) registered a modest 2.1% YoY growth to ₹68 Crore, although it saw a substantial 58.5% surge QoQ.
Financial Deep Dive
The company's financial performance in Q3 FY26 was bolstered by several factors. The Contract Development and Manufacturing Organization (CDMO) segment, Akums' largest, grew revenue by 16.3% YoY, fueled by increased volumes. The Domestic and International Branded Formulation businesses also showed positive momentum, with revenues up 4.2% and 18% YoY, respectively. Notably, the API (Active Pharmaceutical Ingredient) segment, which has been loss-making, saw its losses reduce significantly, indicating a move towards breakeven.
Akums maintains a strong balance sheet with a cash surplus of ₹1,573 Crore. Cash flow from operations was robust at ₹1,109.5 Crore for the nine months ended FY26, translating to a free cash flow of ₹944.5 Crore, demonstrating the company's ability to generate cash from its core business activities. Capital expenditure for the nine-month period stood at ₹165 Crore.
Strategic Initiatives & Future Outlook
Looking ahead, Akums is strategically expanding its global footprint. The company received EU GMP (European Union Good Manufacturing Practice) accreditation for its oral liquids facility in Europe, with supplies expected to commence in FY28. Its oral solid facility also had its EU GMP renewed, and supplies to Europe have already begun. A significant European CDMO contract, valued at EUR 35 million annually, is in place until December 2032, with expected margins in the 'teens'. Furthermore, progress on the Zambian project is on track, with commercial supplies from Indian plants expected in H1 FY27 and operations from the Zambia facility anticipated by CY28.
Investment in automation, including the initiation of a SAP S/4HANA transformation and implementation of Darwinbox for HR, signals a focus on operational efficiency.
The management has guided for double-digit volume growth in Q4 FY26 and expects the domestic business to match industry growth from FY27 onwards, with growth drivers firmly in place. The focus for regulated markets is primarily on Europe, with the API business undergoing a portfolio rationalization aimed at achieving breakeven.
The Grill: Risks and Governance Concerns
Despite the positive financial and strategic updates, Akums faces significant challenges. The most prominent is the ongoing Income Tax search and seizure operation initiated in January 2025. The company has stated that the 'potential impact of these proceedings on the financial results is currently unascertainable' [25], creating substantial uncertainty and potential future liabilities. This investigation follows a previous incident where Akums paid a fine to the NSE in September 2025 for non-compliance with Regulation 17(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, related to the composition of its Board of Directors [10, 18].
Historically, in June 2016, the UK's MHRA ordered a recall of four batches of progesterone produced at Akums's facility due to critical deficiencies, including 'sterility assurance' issues and a lack of robust environmental monitoring [8]. While this is an older event, it highlights past quality control concerns in regulated markets.
Adding to the concerns, the company's standalone PAT saw a sharp 31.71% YoY decline in Q3 FY26, with expenses rising faster than revenue [25]. The injectables facility also continues to operate at low utilization with minimal revenue contribution and significant EBITDA losses [Input].
Peer Comparison & Big Picture
The Indian CDMO market is a burgeoning sector, with market size projected to grow significantly, potentially reaching USD 15.4 billion by 2033 at a CAGR of 7.7% [7]. Akums operates in a competitive landscape alongside major players like Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Cipla, and Dr. Reddy's Laboratories [26]. While Akums has shown strong revenue growth this quarter, its historical sales growth has been modest [19]. Competitors like Divi's Labs and Sun Pharma often command higher margins and more consistent profitability. Akums's strength lies in its large-scale manufacturing capabilities and cost-effectiveness, particularly in generic formulations and CDMO services [17]. The company's focus on European expansion aligns with broader industry trends of Indian CDMOs moving up the value chain and gaining entry into regulated markets [13, 17]. However, the ongoing IT probe and past regulatory issues could impede its ability to fully capitalize on these market opportunities.
The long-term direction for Akums hinges on successfully navigating the current investigations, improving standalone profitability, and leveraging its growing international presence. Investors will be watching closely for resolutions to the tax investigation and continued execution on its strategic growth plans.